에 대한 최신 뉴스 Novo Nordisk (OTC:NONOF) 주식

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

NOVO NORDISK A/S B NEW by Novo-Nordisk A/S

Novo Nordisk AS

Impax Global Social Leaders Fund Q3 2024 Commentary

Novo Nordisk new obesity therapy CagriSema outperforms semaglutide in Phase 3 trial

Novo Nordisk Stock: A Rare Buying Opportunity

Novo Nordisk: CagriSema Underwhelms In REDEFINE-1 Trial

Why is Novo Nordisk crashing after data for next-gen weight loss drug?

Lazard International Equity Advantage Portfolio Q3 2024 Commentary

Lazard International Equity Select Portfolio Q3 2024 Commentary

Lazard International Strategic Equity Portfolio Q3 2024 Commentary

Pfizer: Time And Patience Ran Out (Rating Downgrade)

Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived

AMGN

ASML

ASMLF

BABA

BABAF

BLMIF

BMBLF

BXBLY

CTTAF

CTTAY

DUOL

EBAY

HLNCF

ICLR

INTU

ISRG

JDCMF

KRYAF

KRYAY

MBLY

MELI

NCLTF

NCLTY

NONOF

RNECF

RNECY

SHMZF

SNROF

VKTX

WOLTF

WTKWY

XNGSF

XNGSY

Novo Nordisk

Comments

Novo Nordisk

뉴스

에 대한 최신 뉴스 Novo Nordisk (OTC:NONOF) 주식

뉴스

파트너 / 기고자

벤징가 글로벌